ライフサイエンスコーパス: very-low-density lipoprotein

1 oxidation and export (as triglyceride within very low-density lipoprotein).

2 without significant changes in plasma TG or very low density lipoprotein.

3 ype EL, whereas LPL only mediated binding of very low density lipoprotein.

4 structural diversity in olive oil and human very-low density lipoprotein.

5 ch was due to a decrease in the secretion of very low density lipoproteins.

6 creased hepatic secretion of TG into nascent very low density lipoproteins.

7 t dictates the synthesis of chylomicrons and very low density lipoproteins.

8 poC-III and apoC-IV levels were decreased in very low-density lipoproteins.

9 suggesting that it arises from lipolysis of very-low-density lipoproteins.

10 Indeed, LpL mediated hydrolysis of very-low-density lipoprotein activated PPARalpha in card

11 pairment in their catabolism of remnants and very low-density lipoprotein, an effect that was entirel

12 Atherogenic very low density lipoprotein and intermediate density li

13 tion and considerably decreases synthesis of very low density lipoprotein and its secretion in both l

14 of a subset of apolipoproteins implicated in very low density lipoprotein and triglyceride metabolism

15 a massive uptake of yolk precursors such as very low density lipoprotein and vitellogenin.

16 nmol/L versus TT, 57.0+/-4.5 nmol/L; P=0.03) very low-density lipoprotein and chylomicron particle nu

17 ations, the variant was also associated with very low-density lipoprotein and high-density lipoprotei

18 ein B (apoB), the major protein component of very low-density lipoprotein and low-density lipoprotein

19 concentration of proatherogenic lipoproteins very low-density lipoprotein and low-density lipoprotein

20 in the maternal circulation, maternal plasma very low-density lipoprotein and other lipoproteins are

21 Very low-density lipoprotein and triglyceride concentrat

22 metabolism, especially in the biogenesis of very low-density lipoproteins and chylomicrons via the t

23 ng aetiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism

24 oward less high-density lipoprotein and more very-low-density lipoprotein and triglyceride particles

25 ipoproteins, including low-density (LDL) and very-low-density lipoproteins and chylomicrons.

26 ity lipoprotein cholesterol, a surrogate for very-low-density lipoproteins and low-density lipoprotei

27 6449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprote

28 Serum triglyceride, very-low-density lipoprotein, and apolipoprotein B level

29 triglyceride secretion, lower lipidation of very-low-density lipoproteins, and increased lipid dropl

30 Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density

31 ptotic activity of HDL is inhibited by APOE4 very-low-density lipoprotein (APOE4-VLDL) in endothelial

32 This tempers triglyceride availabiity for very low density lipoprotein assembly and allows homeost

33 sm, and fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion.

34 protein B-100 (apoB-100), and beta-migrating very low-density lipoprotein (beta-VLDL) particles, whic

35 sulfate and 2-O-sulfate groups did not block very low density lipoprotein binding and uptake in isola

36 1-tg mice had increased secretion of hepatic very low density lipoprotein but maintained plasma trigl

37 sma from apoA-I(-/-) mice or purified low or very low density lipoproteins but readily opacified HDL.

38 plasmic reticulum export of chylomicrons and very low-density lipoproteins, but not collagen XII.

39 terols isolated from liver, bile, and plasma very low density lipoprotein by a variant of ISA designe

40 arily because of its role in the assembly of very low density lipoproteins by the liver and chylomicr

41 the secretion of cholesteryl ester-enriched very low density lipoproteins by the liver.

42 ty lipoprotein, low-density lipoprotein, and very-low-density lipoprotein, can be easily separated an

43 D-PDMP affected very-low-density lipoprotein catabolism by increasing th

44 C), low density lipoprotein cholesterol, and very low density lipoprotein cholesterol (VLDL-C) assess

45 After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels

46 measurements revealed a 3.6-fold decrease of very low density lipoprotein cholesterol in serum and a

47 d fasting levels of plasma triglycerides and very low density lipoprotein cholesterol, and increased

48 rcumference, triglycerides, body mass index, very low density lipoprotein cholesterol, lipoprotein A,

49 actor of 5 for the ratio of triglycerides to very low-density lipoprotein cholesterol (TG:VLDL-C); ho

50 l fibres reviewed reduced total cholesterol, very low-density lipoprotein cholesterol (VLDL-C) and LD

51 patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

52 acylglycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

53 2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%)

54 at individual CpGs as a function of fasting very-low-density lipoprotein cholesterol and triglycerid

55 , hypoxia increased hepatic SCD-1 and plasma very-low-density lipoprotein cholesterol levels and indu

56 lic blood pressure, triglyceride levels, and very-low-density lipoprotein cholesterol levels, lesser

57 concentrations of triglyceride and low- and very-low-density lipoprotein cholesterol than controls,

58 mean concentrations of triglycerides (TGs), very-low-density lipoprotein cholesterol, and glucose we

59 triacylglycerols, apolipoprotein A-I and B, very-low-density lipoprotein cholesterol, and lipoprotei

60 Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides,

61 first and rate-limiting step in chylomicron/very low density lipoprotein clearance at the luminal su

62 of macrophage LRP decreased uptake of (125)I-very-low-density lipoprotein compared with wild-type cel

63 ssociation results for medium and very large very low-density lipoprotein composition are unlikely to

64 B level, concentration and particle size of very-low-density lipoproteins, concentration of low-dens

65 significantly change serum triglycerides or very-low-density lipoprotein concentrations.

66 lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I

67 studies with [(3)H]cholesteryl ether-labeled very-low-density lipoproteins demonstrated that the HL/E

68 nonexchangeable protein in chylomicrons and very low-density lipoprotein-derived lipoprotein particl

69 lipoprotein substrate triglyceride content (very low density lipoprotein >> LDL > high density lipop

70 enesis of both apoB48 and apoB100-containing very low density lipoprotein in addition to a phospholip

71 olesterol into apoB-containing lipoproteins (very low density lipoprotein, intermediate density lipop

72 y lipoprotein levels and increased uptake of very low-density lipoprotein into Cxcr7-expressing white

73 (HDL) to the proatherogenic low-density and very low-density lipoproteins (LDL and VLDL).

74 uction in fasting plasma triacylglycerol and very low-density lipoprotein level coupled with slight i

75 Treatment with CCX771 reduced circulating very low-density lipoprotein levels but not low-density

76 0% less body weight gain and lower serum and very low-density lipoprotein levels of triglycerides but

77 er high-density lipoprotein lipids and lower very-low-density lipoprotein lipids, glucose levels, bra

78 poprotein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylom

79 They exist in three major classes: very-low-density lipoprotein, low-density lipoprotein, a

80 rosclerosis, considering they also had lower very low-density lipoprotein/low-density lipoprotein cho

81 No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, hi

82 plasma total, high-density lipoprotein, and very-low-density lipoprotein/low-density lipoprotein cho

83 n, 95% confidence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chai

84 ether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lip

85 ngivalis levels was directly correlated with very low-density lipoprotein (P = 0.03) and triglyceride

86 protein subclasses were shifted toward lower very-low-density lipoprotein (P<0.001) and higher large

87 infusion, followed by measurement of labeled very low-density lipoprotein palmitate via gas chromatog

88 MD -1.51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%;

89 0.70, 95% CI 0.65-0.76, p = 2x10(-)(1)(8)), very-low-density lipoprotein particle size (HR 0.69, 95%

90 rly in therapy, whereas TG concentration and very-low-density lipoprotein particle size decreased con

91 reassembly of triacylglycerols that lipidate very low density lipoprotein particles as part of a hepa

92 at the assembled virions piggy-back onto the very low density lipoprotein particles for secretion.

93 Exported very-low density lipoprotein particles were isolated for

94 DL particles (0.77, 0.60-0.99, P=0.045), and very-low-density lipoprotein particles (0.78, 0.61-0.99,

95 mall LDL (0.78, 0.61-1.00, P=0.05) and small very-low-density lipoprotein particles (0.78, 0.62-0.99,

96 s, LDL particles, and select subfractions of very-low-density lipoprotein particles and LDL particles

97 zed with increasing levels of triglycerides, very-low-density lipoprotein particles, LDL-P, sdLDL-C,

98 ze and concentrations of LDLNMR and VLDLNMR (very-low-density lipoprotein) particles were negatively

99 s C virus (HCV) particles assemble along the very low density lipoprotein pathway and are released fr

100 e appearance in nonesterified fatty acid and very-low-density lipoprotein pools was negatively associ

101 Procollagens, pre-chylomicrons, and pre-very low-density lipoproteins (pre-VLDLs) are too big to

102 ing, quantitative polymerase chain reaction, very-low-density lipoprotein production, adenovirus over

103 Activation of very low density lipoprotein receptor (VLDLR) and apolip

104 Reelin signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolip

105 to apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and is int

106 We discovered that miR-200c targets the very low density lipoprotein receptor (Vldlr) and its li

107 ApoE Receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR) are type I

108 The very low density lipoprotein receptor (VLDLR) is a membe

109 Previously, we have shown that very low density lipoprotein receptor (VLDLR) is virtual

110 induced choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout m

111 scular entothelial growth factor [VEGF], and very low density lipoprotein receptor [VLDLR]) were test

112 Very low density lipoprotein receptor gene knock-out (Vl

113 ails of the lipoprotein receptors ApoER2 and very low density lipoprotein receptor through an amino-t

114 y, including the receptors ApoER2 and VLDLR (very low density lipoprotein receptor) and the adapter p

115 r domains of apolipoprotein E receptor 2 and very low density lipoprotein receptor, Dab1 is preferent

116 ells via apolipoprotein E receptor 2 and the very low density lipoprotein receptor, resulting in the

117 (d), approximately 30 nM) but not to soluble very low density lipoprotein receptor.

118 The very low-density lipoprotein receptor (VLDLR) knockout (

119 le pathways including through the receptors, Very low-density lipoprotein receptor (Vldlr), Apolipopr

120 Mice deficient in another Reelin receptor, very low-density lipoprotein receptor (VLDLR), had norma

121 gnaling pathway that requires its receptors, very low-density lipoprotein receptor and apolipoprotein

122 ation and vascular leakage in the eyecups of very low-density lipoprotein receptor knockout mice, a m

123 Very low-density lipoprotein receptor mutant mice (Vldlr

124 uncation disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2

125 an interaction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirm

126 l blood vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-

127 revealed a point mutation, c.2239C>T, in the very-low-density lipoprotein receptor (Vldlr) gene.

128 Very-low-density lipoprotein receptor (VLDLR) in knockou

129 Very-low-density lipoprotein receptor (VLDLR) is a multi

130 The very-low-density lipoprotein receptor (VLDLR) negatively

131 Very-low-density lipoprotein receptor (Vldlr), which is

132 retinopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient

133 by binding to the two lipoprotein receptors, very-low-density lipoprotein receptor and apolipoprotein

134 ER2 (apolipoprotein E receptor 2) and VLDLR (very-low-density lipoprotein receptor).

135 e gene expression for lipoprotein lipase and very-low-density lipoprotein receptor.

136 rs, apolipoprotein E receptor 2 (Apoer2) and very-low-density lipoprotein receptor.

137 eceptors for Reelin, including integrins and very-low-density lipoprotein receptor/apolipoprotein E2

138 the brain involves the binding of Reelin to very-low-density lipoprotein receptors (VLDLR) and apoli

139 ticles such as very low density lipoprotein, very low density lipoprotein remnants, and intermediate-

140 (surrogates for low-density lipoproteins and very-low-density lipoproteins, respectively), the RR was

141 lls to acetylated low-density lipoprotein or very low density lipoprotein resulted in a time- and con

142 and increased secretion of triglyceride-rich very low density lipoprotein resulting in hypertriglycer

143 els were associated with both a reduction in very low density lipoprotein secretion and an increase i

144 ombined effect of inhibition of lipogenesis, very low density lipoprotein secretion and export of tri

145 Despite increased very low density lipoprotein secretion, apoB/BATless mic

146 cal increase in both hepatic lipogenesis and very low density lipoprotein secretion.

147 nhibiting hepatic triglyceride synthesis and very low density lipoprotein secretion.

148 miR-34a inhibits very low-density lipoprotein secretion and promotes live

149 Blocking hepatic very low-density lipoprotein secretion through genetic o

150 genes involved in fatty acid beta-oxidation, very low-density lipoprotein secretion, and transcriptio

151 Choline metabolism is important for very low-density lipoprotein secretion, making this nutr

152 cal mechanisms and consequences of defective very low-density lipoprotein secretion.

153 and inadequate increases in IHTG export via very low-density lipoprotein secretion.

154 Very-low-density lipoprotein secretion, which is absent

155 atic free fatty acid oxidation, or decreased very-low-density lipoprotein secretion.

156 , via mitochondrial beta-oxidation and VLDL (very low density lipoprotein) secretion, causes excessiv

157 ewly formed lipid droplets, and yolk-derived very low density lipoprotein, shown to be efficiently en

158 protein distribution preference of apoE4 for very low density lipoprotein-sized particles.

159 sity lipoprotein cholesterol subclasses, and very-low-density lipoprotein subclasses did not improve

160 events was also observed for several LDL and very-low-density lipoprotein subfractions but not for io

161 CVD/all-cause death, as were several LDL and very-low-density lipoprotein subfractions, albeit with a

162 maller increases of most components of VLDL (very low density lipoprotein) subparticles.

163 nover, which drives hepatic triglyceride and very low-density lipoprotein synthesis.

164 Mttp produced a dramatic reduction in plasma very low density lipoprotein-TG and virtually eliminated

165 the increase in LPL activity, the uptake of very low density lipoprotein-TG is markedly reduced in a

166 er of surface components of chylomicrons and very low density lipoprotein to high density lipoprotein

167 ally derived chylomicrons and injected human very low density lipoproteins to the same extent as obse

168 Uptake of DiI-labeled very low-density lipoprotein to adipose tissue was deter

169 mol/min for LowLF; P = .41) or production of very-low-density lipoprotein triacylglycerol from FFAs (

170 -IV, C-II, and C-III and increases serum and very low density lipoprotein triglyceride levels.

171 men and women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palm

172 ect has been shown to be caused by decreased very low-density lipoprotein triglyceride secretion rate

173 incorporation into palmitate of circulating very low-density lipoprotein triglyceride.

174 , where rs964184 was associated with various very low density lipoprotein, triglyceride, and high-den

175 ants caused only a small increase in hepatic very low density lipoprotein-triglyceride secretion.

176 were used to assess insulin sensitivity and very-low-density lipoprotein-triglyceride (VLDL-TG) secr

177 rate decreased by 27% +/- 7% (P < .01); and very-low-density lipoprotein-triglyceride secretion rate

178 emic free fatty acids (FFA) into circulating very low-density lipoprotein triglycerides (VLDL-TGs) un

179 Rs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postpr

180 sociations were observed for extremely large very-low-density lipoprotein triglycerides (odds ratio [

181 ajor role in promoting uptake of circulating very low density lipoprotein-triglycerides (VLDL-TGs) in

182 pact of anti-miR-33 therapy on the levels of very low-density lipoprotein-triglycerides (VLDL-TAG).

183 ) dictates the formation of chylomicrons and very low-density lipoproteins, two major lipoprotein pre

184 (a), and triglyceride-rich particles such as very low density lipoprotein, very low density lipoprote

185 ot related with the immune system, including very-low-density lipoprotein, vitellogenin, estrogen rec

186 Abnormalities in very low density lipoprotein (VLDL) assembly and secreti

187 ridemia was due largely to overproduction of very low density lipoprotein (VLDL) by the liver, a norm

188 Nascent very low density lipoprotein (VLDL) exits the endoplasmi

189 uptake of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles by a singl

190 The transport of nascent very low density lipoprotein (VLDL) particles from the e

191 In contrast, the very low density lipoprotein (VLDL) pathway, which is re

192 This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the

193 incubations of apoA-I(-)(/)(-) apoE(-)(/)(-) very low density lipoprotein (VLDL) resulted in a 3-fold

194 intrahepatic triglyceride (IHTG) content and very low density lipoprotein (VLDL) triglyceride (TG) se

195 correlated to insulin resistance and plasma very low density lipoprotein (VLDL) triglycerides concen

196 sma apolipoprotein B yet increased levels of very low density lipoprotein (VLDL) triglycerides, sugge

197 erum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference i

198 (LDL) density lipoprotein as lipid donor to very low density lipoprotein (VLDL), and the preference

199 correlate with metallocorrole affinities for very low density lipoprotein (VLDL), the main carrier of

200 cells do not express MTP and cannot secrete very low density lipoprotein (VLDL), yet they do not acc

201 ted apoE in accounting for the difference in very low density lipoprotein (VLDL)-induced adipocyte tr

202 easurements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays

203 oth human high density lipoprotein (HDL) and very low density lipoprotein (VLDL).

204 toma cells can mediate binding and uptake of very low density lipoprotein (VLDL).

205 ed for the hepatic assembly and secretion of very low density lipoprotein (VLDL).

206 h a Golgi-dependent mechanism while bound to very low density lipoprotein (vLDL).

207 In contrast, serum levels of very low density lipoprotein (VLDL)/low density lipoprot

208 n the hepatic secretion of apoB-100-carrying very low density lipoproteins (VLDL) and a decrease in t

209 core lipid in the assembly and secretion of very low density lipoproteins (VLDL) has been of interes

210 HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identi

211 The major protein component in secreted very low density lipoproteins (VLDL) is apoB, and it is

212 accelerated hepatic fatty acid oxidation and very low density lipoproteins (VLDL) secretion.

213 transient depression of hepatic secretion of very low density lipoproteins (VLDL).

214 riglyceride into plasma through secretion of very low density lipoproteins (VLDL).

215 iating FFA uptake or triglyceride release as very low density lipoproteins (VLDL).

216 oprotein (HDL(NMR)), 1.71 (1.38 to 2.12) for very low-density lipoprotein (VLDL(NMR)), and 2.25 (1.80

217 00014; African Americans P = 0.00417), large very low-density lipoprotein (VLDL) (Caucasians P = 0.00

218 the accumulation of free cholesterol in the very low-density lipoprotein (VLDL) and HDL region, and

219 apo) E between lipoprotein particles such as very low-density lipoprotein (VLDL) and high-density lip

220 idemia, the esterification of cholesterol of very low-density lipoprotein (VLDL) and high-density lip

221 usly found that EL is capable of hydrolyzing very low-density lipoprotein (VLDL) and LDL lipids ex vi

222 Very low-density lipoprotein (VLDL) and LDL plasma level

223 ) and the apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) and low-density lipo

224 hydrolase (Ces3/TGH) participates in hepatic very low-density lipoprotein (VLDL) assembly and in adip

225 ty lipoprotein (LDL) cholesterol level, high very low-density lipoprotein (VLDL) cholesterol level, h

226 de (TG) levels resulting both from increased very low-density lipoprotein (VLDL) clearance and decrea

227 n decreased cholesterol levels and decreased very low-density lipoprotein (VLDL) fractions.

228 Increased production of very low-density lipoprotein (VLDL) is a critical featur

229 TGs, hepatosteatosis, and secrete lipid-poor very low-density lipoprotein (VLDL) lacking arachidonoyl

230 ue mass, and adipocyte cell size and reduced very low-density lipoprotein (VLDL) levels, as compared

231 monstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by m

232 ting impaired ER-to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

233 NDGA inhibited very low-density lipoprotein (VLDL) secretion by affecti

234 ic pathways, such as triglyceride synthesis, very low-density lipoprotein (VLDL) secretion, and fatty

235 attenuation of hepatic steatosis, increased very low-density lipoprotein (VLDL) secretion, and impro

236 ignaling pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subse

237 erized by a 3-fold higher liver secretion of very low-density lipoprotein (VLDL) that had apoC-III bu

238 by mitochondrial oxidation and secretion as very low-density lipoprotein (VLDL) triglycerides.

239 ein (HDL) subclasses and decreased levels of very low-density lipoprotein (VLDL), amino acids, and ci

240 mbination of size and concentrations of LDL, very low-density lipoprotein (VLDL), and high-density li

241 ined the lipidation and secretion of nascent very low-density lipoprotein (VLDL), finding that liver

242 h is needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of ci

243 experiments demonstrate that the LDLR has a very low-density lipoprotein (VLDL)-induced, FDNPVY-inde

244 apoCII levels and increased apoB48 levels in very low-density lipoprotein (VLDL)/intermediate-density

245 DL are further isolated by precipitating the very low-density lipoproteins (VLDL) and low-density lip

246 (CE), and triglyceride (TG) from plasma and very low-density lipoproteins (VLDL) was used to measure

247 Raman signature of single optically trapped very low-density lipoproteins (VLDL), a subclass of TGRL

248 re to triglyceride-rich lipoproteins such as very low-density lipoproteins (VLDL).

249 Excessive secretion of triglyceride-rich very low-density lipoproteins (VLDL-TG) contributes to d

250 in (HDL), low-density lipoprotein (LDL), and very-low density lipoprotein (VLDL), play a critical rol

251 Cardiac utilisation of very-low-density lipoprotein (VLDL) and chylomicrons (CM

252 Very-low-density lipoprotein (VLDL) and chylomicrons (CM

253 fects were mainly on serum triglycerides and very-low-density lipoprotein (VLDL) and its subclasses,

254 NT ASO exhibited a significant impairment in very-low-density lipoprotein (VLDL) binding that was ent

255 protein, high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) cholesterol levels.

256 36 had significantly lower plasma TC, LDL-C, very-low-density lipoprotein (VLDL) cholesterol, and MDA

257 n of CETP were stronger on lower remnant and very-low-density lipoprotein (VLDL) cholesterol, but the

258 in plasma low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) discriminated dengue

259 the notion that HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

260 y reduced triglycerides and large and medium very-low-density lipoprotein (VLDL) particle concentrati

261 patitis C virus (HCV) uses components of the very-low-density lipoprotein (VLDL) pathway for assembly

262 hepatic triglycerides (TAG) associated with very-low-density lipoprotein (VLDL) play a major role in

263 FPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothe

264 ght but is associated with increased hepatic very-low-density lipoprotein (VLDL) secretion and elevat

265 glyceride content by threefold and decreased very-low-density lipoprotein (VLDL) secretion by 50%.

266 oaches, we demonstrate that vigilin controls very-low-density lipoprotein (VLDL) secretion through th

267 TG content, we measured hepatic lipogenesis, very-low-density lipoprotein (VLDL) secretion, and lipid

268 Genes for very-low-density lipoprotein (VLDL) synthesis (microsoma

269 rcise prevents fructose-induced increases in very-low-density lipoprotein (VLDL) triglycerides by dec

270 spectrometric analysis suggested that serum very-low-density lipoprotein (VLDL) was responsible for

271 -48-containing TRLs and apo B-100-containing very-low-density lipoprotein (VLDL), as well as on the e

272 inal) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density l

273 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100

274 ic and proteomic profiles implicated these 3 very-low-density lipoprotein (VLDL)-associated apolipopr

275 a marked suppression of the plasma levels of very-low-density lipoprotein (VLDL)-associated triglycer

276 e important for HCV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse ser

277 e observed strong positive associations with very-low-density lipoprotein (VLDL)-lipoproteins, VLDL-c

278 Very-low-density lipoprotein (VLDL)-triacylglycerols and

279 uh7 cells via pathways distinct from that of very-low-density lipoprotein (VLDL).

280 TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density li

281 Very-low-density lipoproteins (VLDL) are metabolic precu

282 Very-low-density lipoproteins (VLDL) is a hallmark of me

283 in a manner that parallels the formation of very-low-density lipoproteins (VLDL).

284 rocessed human milk and O-glycoproteins from very-low-density-lipoprotein (vLDL) particles.

285 Here we show that maternal very-low-density-lipoprotein (VLDL) receptor deletion in

286 protein (HDL) yields 4-6% of the LDL signal, very-low-density-lipoprotein (VLDL) yields 1-3%, and hum

287 iglyceride (TAG)-rich lipoproteins including very low density lipoproteins (VLDLs) and chylomicrons,

288 epatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted

289 ip between CD36 expression and serum HDL and very low-density lipoproteins (VLDLs) levels was also ex

290 lesterol and triglycerides, respectively, in very low-density lipoproteins (VLDLs).

291 ccomplished primarily through the actions of very low-density lipoproteins (VLDLs).

292 fasting triacylglycerol in chylomicrons and very-low-density lipoproteins (VLDLs) (P = 0.004), reduc

293 actor ANOVA) in plasma (P = 0.023) and large very-low-density lipoproteins (VLDLs) (P = 0.016) and po

294 at transfers alpha-tocopherol (vitamin E) to very-low-density lipoproteins (VLDLs).

295 ty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs).

296 was observed in systolic BP (7.1 mm Hg) and very-low-density lipoproteins (VLDLs; 5.16 mg/dL) in gro

297 in B (apoB)-containing lipoproteins (hepatic very-low density lipoproteins), which leads to hyperlipi

298 ich lipoproteins, including chylomicrons and very low density lipoprotein, which is the precursor to

299 cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of sm

300 by the inability to produce chylomicrons or very low-density lipoproteins, with the absence of apoli